Embleema

Embleemas software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project ARGOS). In addition to the FDA, our platform powers the Lupus Landmark Study, the largest clinical study...

Blockchain,healthcare technology,electronic medical records,healthcare,clinical research,clinical trials,medicine,technology,genomics,bioinformatics,and precision medicine

Embleema operates in the Hospitals and health care industry.

Embleema's revenue is 1m - 10m

Embleema has 11 - 50 employees.